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Abstract
Background: Breast milk provides nutrition for infants and also contains a variety of bioactive factors that influence
the development of the newborn. Human milk is a complex biological fluid that can be separated into different
layers (water phase and lipid phase with its component water and lipid fractions). It can affect the developing
human body along the whole length of the gastrointestinal tract, and through the circulation, its factors may reach
every organ.
Methods: In the present study, we analyzed milk samples collected monthly for 6 months from 16 mothers from
the 4th week postpartum between 2014 and 2016 in Baranya County, Hungary. The 96 samples provided us
information about the fluctuation of certain bioactive factors during the first 6 months of lactation. We investigated
with Luminex technology the concentrations of several cytokines (CD40, Flt-3L), chemokines (MCP-1, RANTES, GRO,
MIP-1ß, MDC, eotaxin, fractalkine), and epidermal growth factor (EGF). Paired t-tests and one-way ANOVA followed
by Bonferroni post-hoc tests were used to compare the data.
Results: We detected the presence of each bioactive factor in every layer of the milk samples during the first 6 months
of breastfeeding in widespread concentration ranges. In the case of GRO, MIP-1ß, MDC, Flt-3L, fractalkine, and eotaxin,
the concentrations were constant during the first 6 months of lactation. The water phase of human milk contained
higher factor concentrations compared to both fractions of the lipid phase for most factors (except eotaxin and
MIP-1ß). The concentrations of CD40, EGF, MCP-1, and RANTES in the first 3 months were significantly different
compared to the values detected between 4th and 6th months. In the water phase, the level of MCP-1 was significantly
decreased, while all of the other factors increased during the 4th through 6th months. We found significantly higher
EGF, GRO, and RANTES levels in the water fraction compared to the lipid fraction of the lipid phase.
Conclusions: The novel findings of this investigation were the presence of Flt-3L and MDC in all layers of breast milk,
and nearly all bioactive factors in the lipid phase. Due to their widespread physiological effects these factors may have
an essential role in organogenesis.
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Background
Human milk is a complex biological fluid uniquely suited
to the infant. Its quantity and composition are constantly
changing during lactation and are influenced by numerous
factors [1–3]. It promotes survival and development of the
newborn due to its nutritional composition and
non-nutritive bioactive factors, including growth factors,
hormones and immunological factors, such as chemokines
and cytokines with different physiological effects. The
distribution and level of the bioactive factors vary widely in
the milk [4, 5], and the exact role and effects of these
factors during postnatal adaptation are still under investiga-
tion. These biologically active molecules are proven to
protect the newborn from different infections affecting the
respiratory and gastrointestinal tract [6, 7] and have an
important role in gaining immunocompetence [8, 9]. In
addition to the immunological effects they contribute to
organogenesis and they are essential for the development* Correspondence: andreatamassz@gmail.com1Department of Anatomy, MTA-PTE PACAP Research Group, Centre for
Neuroscience, Medical School, University of Pécs, Pécs, Hungary
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Vass et al. International Breastfeeding Journal            (2019) 14:9 
https://doi.org/10.1186/s13006-019-0203-3
and adequate functioning of the nervous, gastrointestinal
and cardiovascular systems [10].
Bioactive components of human milk come from a
variety of sources; some are produced and secreted by the
mammary epithelium or by cells carried within the milk,
while others are drawn from maternal serum and
transferred across the mammary epithelium by
receptor-mediated transport [10]. Previous studies have
proven that human breast milk is segregable into water
and lipid phases using different separation techniques.
Preclinical and clinical studies have analyzed mainly the
water phase of milk. However, breast milk has a complex
lipid architecture [11] that forms a special biological
colloidal system [12]. Typically, the fat content of mature
human milk is about 4 g/dL. The lipid phase can be
further divided into water and lipid fractions with
additional separation techniques. The lipid fraction con-
tains milk fat globules (MFG), secreted by the mammary
epithelial cells; and their size varies from 0.2 to more than
15 μm [13]. The milk fat globules secreted into breast milk
are made up of four layers (from inside, in order): a single
layer of polar lipids and proteins, an entrained cytoplasm
layer (10–20 nm wide) and a double layer of polar lipids,
proteins, glycoprotein and cholesterol [14, 15]. The inner
monolayer membrane originates from the endoplasmic
reticulum, while the outer bilayer originates from the
apical plasma membrane. The bioactive factors are found
in the cytoplasm layer; this way they are protected during
the transition through the gastrointestinal tract. Therefore,
the contents of MFG are able to directly influence the
composition of microbiota or colonization of the gut and
also to absorb into the circulation [16, 17].
Only limited data are available about the content of
bioactive factors during the first months of lactation
[10]. Therefore, the aim of the present study was to
examine the presence and changes in concentration of
different bioactive factors during the first 6 months of
lactation, which is the most critical period of postnatal
adaptation and when exclusive breastfeeding is recom-
mended. Our applied separation protocol allows us to
separately analyze the composition of the water phase
and the two fractions of the lipid phase involving the
protected cytoplasm layer within the MFG. In our study
we focused on the following bioactive agents in the three
distinct layers: epidermal growth factor (EGF); cytokines:
soluble cluster of differentiation 40 ligand (CD40), and
FMS-like tyrosine kinase 3 ligand (Flt-3L); and chemo-
kines: monocyte chemoattractant protein-1 (MCP-1),
regulated on activation, normal T cell expressed
and secreted (RANTES), macrophage inflammatory
protein-1beta (MIP-1β), macrophage-derived chemokine
(MDC), growth-regulated oncogene (GRO), eotaxin, and
fractalkine. Cytokines and chemokines, such as CD40,
MCP-1, RANTES, MIP-1β, and MDC play important
roles in the modulation of immune responses and the
regulation of immune cell migration [18–22]. Flt-3L is
responsible for hematopoietic stem cell progenitor pro-
liferation [23]. With this effect Flt-3L is involved in the
development of the cardiovascular system similarly to
GRO, which can stimulate endothelial proliferation dur-
ing neovascularization [24]. Fractalkine and eotaxin are
involved in the neurogenesis and the development of
synaptic plasticity [25, 26]. Some bioactive factors can
also help the adaptation of the gastrointestinal system,
for example EGF enhances the differentiation and prolif-
eration of enteral cells and the development of cell adhe-
sions between hepatic and intestinal cells [27]. Since
these factors have proven widespread effects, it would be
beneficial to know their exact distribution in the three
separated layers of human breast milk.
Methods
Study design
This was a descriptive study in which healthy mothers
agreed to provide samples of breast milk for analysis. Data
collection commenced at four weeks postpartum, and
continued every four weeks until six months postpartum.
Maternal inclusion criteria
Volunteers had delivered full-term infants by spontan-
eous active labor; pregnancy, labor, and postnatal adap-
tation were uneventful. Neither mothers nor infants had
infectious diseases during the examined period. Mothers
involved in the study took Elevit® multivitamin complex
and folic acid tablets regularly; they had no special diet
during pregnancy; all were nonsmokers. Participants –
recruited with the help of health visitors of the Unified
Health Institutions of Pécs – had normal prepregnancy
and postpartum Body Mass Index (BMI) (Table 1). We
included only mothers who were able to give milk
samples at every time point of the investigation. The
mothers used their own pumps to avoid transmission of
infection.
Table 1 Characteristics of participants (n = 16)
Variables
Maternal age (years), mean ± SD 27.8 ± 1.9
Range 25–32
Maternal weight (kg), mean ± SD 67.5 ± 3.4
Range 62–71
Parity
primipara 4
multipara 12
Mode of birth
vaginal delivery 16
Caesarean section 0
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Milk samples
Milk samples were collected between 2014 and 2016 at
the Department of Obstetrics and Gynecology, Univer-
sity of Pécs and at the Unified Health Institutions of
Pécs. We collected 5ml of breast milk from mothers (n
= 16) every fourth week during the first 6 months of
lactation (n = 96 samples). The samples were hindmilk
and were collected between 1 pm and 3 pm. Participants
pumped the entire breast expression into a sterile bottle
and 5ml was poured into polypropylene tubes. We
chose early afternoon as the target time for sample
collection based on a previous report by Kent et al. [28]
showing that milk fat content is lower in night and
morning feedings compared to afternoon and evening
feedings. Since we analyzed the bioactive content of the
lipid layer, we speculated that samples obtained in the
early afternoon might be close to representative of the
average for all samples throughout a 24-h period. The
collected fresh samples were stored at − 20 °C in sterile
polypropylene tubes until analysis.
Separation technique
In the present experiment, we applied different separation
techniques to divide human milk into three different frac-
tions from the original samples [11]. We segregated
human milk into water and lipid phases, then the lipid
phase was further subdivided into water and lipid frac-
tions. To separate the samples into 3 different layers, milk
was centrifuged at 4000 x g for 15min at 13 °C to remove
the pellet which contains the cells. This way we retrieved
a water phase and a lipid phase, containing the milk fat
globules. The lipid layer was suspended in 10mM
phosphate buffered saline (PBS) (pH 7.4) and stored at 4 °
C overnight. Then it was churned with a Turrax at a
medium speed until fat and sera were separated. After a
brief warming at 38 °C, specimens were centrifuged at
100,000 x g for 1 h at 24 °C to obtain the water fraction
and the lipid fraction. Then, the lipid fraction of the lipid
phase was suspended in 10mM PBS (pH 7.4).
Luminex technology
Luminex Multiplex Immunoassay was performed to de-
termine the protein concentrations of the following cyto-
kines/chemokines using customized Milliplex Human
Cytokine/Chemokine Magnetic Bead Panel (Merck
Millipore, Burlington, USA): 1. EGF; 2. eotaxin; 3.
Flt-3L; 4. fractalkine; 5. GRO; 6. MDC; 7. sCD40L; 8.
MCP-1; 9. MIP-1ß; 10. RANTES. Standard curve range
for each of these analytes was 3.2–10,000 pg/ml. Sensi-
tivity (minimum detectable concentration in pg/ml)
values were: EGF: 2.8; eotaxin: 4.0; Flt-3L: 5.4; fractalkine:
22.7; GRO: 9.9; MDC: 3.6; sCD40L: 5.1; MCP-1: 1.9;
MIP-1ß: 3.0; RANTES: 1.2. Following previous optimiza-
tions, all samples were tested undiluted in a blind-fashion
way and in duplicate. The experiment was performed ac-
cording to the manufacturer’s instructions. Briefly, 25 μl of
each sample (control and standard) was added to a
96-well plate (provided with the kit) containing 25 μl of
capture antibody coated, fluorescent-coded beads. Bio-
tinylated detection antibodies and streptavidin-PE were
added to the plate after the appropriate incubation pe-
riods. After the last washing step, 150 μl of sheat fluid was
added to the wells, the plate was incubated and read on
the Luminex100 instrument. Five-PL regression curve
were used to plot the standard curves for all analyte by
the xPonent 3.1 software analysing the bead median fluor-
escence intensity. In the case of eotaxin, Flt-3L, fractalk-
ine, MDC, and RANTES we eliminated from the analysis
those data that were questionable because of the detection
limits of the assays. In the case of RANTES, some of our
data were above the sensitivity limit, but below the
standard curve, so these results were calculated by ex-
trapolation of the standard curve. Results are given in
mean pg/ml ± standard deviation [SD] wet tissue.
Statistical methods
When we compared the concentration values of the first
3 months to the results detected between 4th and 6th
months we applied paired t-tests. One-way ANOVA
followed by Bonferroni post-hoc tests were used to com-
pare the concentration of the factors in the different
layers during the first or second parts of the examin-
ation. Statistical analyses were performed by IBM SPSS
Statistics v20.0 (IBM’s Corporate, New York, USA).
Differences were considered to be significant when p
values were < 0.05. All data are given as mean ± SD.
Results
The mothers ranged in age from 25 to 32 years (Table
1). They ranged in weight from 62 to 71 kg; all had nor-
mal BMIs. Four mothers were primiparous, the others
multiparous. All were delivered vaginally. During the
first six months of lactation, we did not detect any
time-dependent changes in the concentrations of GRO,
MIP-1ß, MDC, Flt-3L, eotaxin, or fractalkine. The aver-
age values of these bioactive factors in the water phase
and in the two layers of the separated lipid phase are
shown in Table 2. We detected significantly higher levels
of GRO, MDC, Flt-3L, and fractalkine in the water phase
compared to both separated fractions of the lipid phase.
No significant differences were detected between the
concentration of MIP-1ß in the water phase and the sep-
arated fractions of the lipid phase. We measured
significantly higher GRO concentration in the water
fraction of the lipid phase compared to the lipid fraction.
Eotaxin concentration in the water phase was similar to
the lipid fraction, and it was not detectable in the water
fraction. We did not detect significant differences
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between the separated fractions of the lipid phase in
MIP-1ß, MDC, Flt-3L, or fractalkine (Table 2).
We found differences in CD40, EGF, MCP-1, and
RANTES concentrations between the first 3 months and
at 4–6months of lactation. The concentrations of these
factors in the water phase are presented in Table 3, and
the factor content of the separated lipid phase is shown
in Table 4. The CD40, EGF, and RANTES levels in the
water phase increased significantly, and the MCP-1 level
decreased significantly with time (Table 3). In the water
fraction of the lipid phase, levels of all factors were
significantly higher in the second (4–6months) part of
the examination period. In the lipid fraction of the lipid
phase, MCP-1 and EGF increased with time, and CD40
and RANTES did not change significantly (Table 4).
In the case of four factors – CD40, EGF, MCP-1, and
RANTES, − we detected significant changes between the
different layers of breast milk during the first (1–3
months) and the second (4–6 months) parts of the
examination period. Comparing to the three layers of
breast milk, the water phase contained significantly
higher levels of CD40, EGF, and MCP-1 during the first
3 months. We detected significantly higher EGF concen-
tration in the water fraction of the lipid phase compared
to the lipid fraction of lipid phase in the first 3 months
of lactation. In the case of CD40, MCP-1, and RANTES
we did not measure significant differences between the
two layers of the lipid phase during the first 3 months of
breastfeeding. During the second part of the examin-
ation period, we detected significantly higher CD40,
EGF, and MCP-1 concentrations in the water phase
compared to the water fraction of the lipid phase. In all
cases, the water phase contained significantly increased
levels of factors compared to the lipid fraction of lipid
phase. When we compared the two layers of the lipid phase,
the water fraction of the lipid phase contained significantly
higher EGF and RANTES concentrations compared to the
lipid fraction of the lipid phase. We did not find differences
in CD40 or MCP-1 level between the two layers of lipid
phase between the 4th and 6thmonths (Fig. 1).
Discussion
In the present study, we detected several bioactive
factors during the first 6 months of lactation in the three
separated layers of human milk: in the water phase and
in the water and lipid fractions of the lipid phase.
Presumably each of these layers has its own role during
organogenesis. The content of the water phase affects
the infant’s body through mucosal absorption from the
oral cavity. The bioactive components in the MFG, because
of the protective lipid layer, directly affect the lower gastro-
intestinal tract, and through the circulation they may affect
the developing human body [10]. Cytokines and chemo-
kines are small soluble factors that modulate biological
Table 2 Concentration of bioactive factors during the first 6 months of lactation [pg/ml]
Factors Water phase (W) Lipid phase (L) p - values
Water fraction (L-WF) Lipid fraction (L-LF)
GRO 5398.36 ± 2250.44 1927.09 ± 563.33 652.36 ± 160.60 W vs L-WF
W vs L-LF
L-WF vs L-LF
< 0.0001
< 0.0001
0.0003
MIP-1ß 6.72 ± 2.58 5.35 ± 0.57 6.23 ± 1.44 W vs L-WF
W vs L-LF
L-WF vs L-LF
0.5280
1.0000
1.0000
MDC 21.48 ± 16.01 11.83 ± 8.15 12.25 ± 8.46 W vs L-WF
W vs L-LF
L-WF vs L-LF
0.0029
0.0069
1.000
Flt-3L 8.81 ± 2.36 6.25 ± 0 6.25 ± 0 W vs L-WF
W vs L-LF
L-WF vs L-LF
0.0235
0.0235
1.0000
eotaxin 9.62 ± 2.54 Not detectable 9.85 ± 3.89 W vs L-LF 0.9227
fractalkine 166.84 ± 81.77 43.29 ± 23.00 25.27 ± 7.13 WP vs L-WF
WP vs L-LF
L-WF vs L-LF
< 0.0001
< 0.0001
0.5774
GRO growth related oncogene; MIP-1ß macrophage inhibitory protein 1ß; MDC macrophage derived chemokine; Flt-3L Flt-3 Ligand
Table 3 Concentration of bioactive factors presented in the
water phase of human milk during the first 6 months of
lactation [pg/ml]
Factors Water phase [W] p-values
1–3 vs
4–6
months
1–3 months 4–6 months
CD40 50.17 ± 2.76 65.77 ± 1.57 < 0.0001
EGF 2234.95 ± 790.45 4064.33 ± 953.71 < 0.0001
MCP-1 2986.49 ± 937.31 306.66 ± 146.57 < 0.0001
RANTES 3.0 ± 0.75 5.18 ± 1.56 0.0273
CD40 cluster of differentiation 40; EGF epidermal growth factor; MCP-1
macrophage chemokine protein-1; RANTES regulated on activation, normal T
cell expressed and secreted
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signals with remarkable capabilities, such as influencing
growth and development, hematopoiesis, and the immune
system through lymphocyte recruitment, T cell subset dif-
ferentiation and inflammation [29, 30].
During postnatal adaptation, the gastrointestinal tract
becomes more actively involved in enteral nutrition [31].
Several research groups have proven that the micro-
biome in infants is an important regulator of developing
subsistence. The human microbiome is a constantly
changing system influenced by hormones, cytokines, and
chemokines. Its development starts at the moment of
birth, and the most important changes occur during the
first year of life [32–35]. The connections between the
brain and gut have been investigated previously; this
communication axis bound by the vagus nerve is
described as the microbiota-gut-vagus-brain axis [36].
Studies have proven the connection of the microbiome
to disorders such as visceral pain, autism spectrum
disorder, cardiovascular risk, obesity, depression, and
sclerosis multiplex [36]. Previous studies suggest that the
gut microbiome modulates molecular mechanisms that
influence allergic reactions [37].
The composition of human milk influences the develop-
ing immune system in the early, critical period of postna-
tal adaptation [38]. Cytokines and chemokines in breast
milk reach the neonatal intestines intact due to the pro-
tection from digestion by protease inhibitors, such as
alpha 1-antichymotrypsin and alpha 1-antitrypsin, which
are present in human milk. In addition, the gastric diges-
tion of proteins is reduced during the first 3 months of life
because of the limited secretion of pepsin and hydrogen
ions and the general immaturity of the newborn’s digestive
abilities. Therefore, these factors can exert their biological
activities in their intact form [39, 40].
Several cytokines are known to play important roles in
the brain, because they are transported across the
blood-brain barrier [41]; the rate of transport varies
among regions and is affected by cellular components of
the blood [42]. The cytokines and chemokines affect cellu-
lar and molecular processes of hippocampal-dependent
long-term memory consolidation and neurogenesis [43].
Chemokines are involved in neurodevelopment and
neurophysiological signaling, and they attract leukocytes
and mediate immune responses in the brain [44].
GRO is a small cytokine belonging to the CXC chemo-
kine family that was previously called GRO1 oncogene,
and now it is called CXCL1. GRO is expressed physiolo-
gically during protective reactions against microbiological
agents or tumor progression [45]. GRO’s chemoattractant
function in neutrophil granulocytes has been described
earlier [18] and it is also known as a mediator of inflam-
matory responses [46]. We detected high amount of GRO
in every phase of breast milk as Radillo and coworkers
found in whole milk samples [47]. It is suggested that
GRO may moderate the development of gut-associated
lymphoid tissue. In neovascularization GRO is necessary
for ideal endothelial cell proliferation [24]. Hence, it may
directly affect the vascularization of the intestinal wall and
through absorption also the extraintestinal vessels of the
body.
Eotaxin, a member of the CC chemokine subfamily,
was present in low concentration in the water phase of
human milk. Previous examinations proved its role in
neurogenesis [25] and plasticity [48]. Other investigators
reported higher concentration of eotaxin in colostrum
and in the first week of lactation [49, 50]. It is possible
that the concentration of eotaxin fluctuates with time
since in our examination this factor was present in low
concentration in every layer. Although it is able to be
transported through the blood-brain-barrier [41], this
factor in these low concentrations may have little effect
on the development of the brain.
A constitutively expressed chemokine named fractalk-
ine in humans and neurotactin in mice [51] is a member
of the CX3C chemokine family. Experiments pointed out
that fractalkine promotes synaptic plasticity in the devel-
oping nervous system. It modulates synaptic transmis-
sion and has long-term potentiation in the hippocampus
[26]. Fractalkine is upregulated in the hippocampus; it
also regulates spatial orientation learning processes.
Based on our work, fractalkine is present in higher
concentrations in the different milk layers than what
others have reported in whole milk [52]. In summary,
fractalkine reaches different parts of the developing
Table 4 Concentration of bioactive factors presented in the lipid phase of human milk during the first 6 months of lactation [pg/ml]
Factors Lipid phase [L]
Water fraction [L-WF] Lipid fraction [L-LF]
1–3 months 4–6 months p- values
1–3 vs 4–6 mo
1–3 months 4–6 months p- values
1–3 vs 4–6 mo
CD40 22.87 ± 7.36 34.11 ± 6.67 0.019 22.98 ± 7.87 29.80 ± 0.01 0.1330
EGF 828.48 ± 480.11 1851.26 ± 456.69 < 0.0001 375.25 ± 129.18 669.11 ± 197.70 < 0.0001
MCP-1 13.02 ± 3.49 21.41 ± 9.71 0.0245 5.07 ± 0.69 10.67 ± 6.01 0.0020
RANTES 3.13 ± 0.73 4.34 ± 0.59 < 0.0001 3.65 ± 1.86 2.37 ± 0.0 0.2031
CD40 cluster of differentiation 40; EGF epidermal growth factor; MCP-1 macrophage chemokine protein-1; RANTES regulated on activation, normal T cell expressed
and secreted; mo months
Vass et al. International Breastfeeding Journal            (2019) 14:9 Page 5 of 10
Fig. 1 (See legend on next page.)
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human body through absorption and it may modulate
neurodevelopment.
The monocyte chemoattractant protein 1 (MCP-1) or
CCL2 (chemokine [C-C motif] ligand 2) is an inducible
cytokine. It is produced by endothelial and epithelial
cells, and fibroblasts and induced by oxidative stress,
growth factors, and other cytokines [53, 54]. MCP-1 reg-
ulates the migration of monocytes, natural killer (NK)
cells, and memory T-lymphocytes [21]. During the first
3 months of lactation, we detected high levels of MCP-1,
which dramatically decreased from the 4th month; we
suggest that this factor particularly plays a role in the
early adaptation of immune system as an influencer of T
cell immunity [55–57]. This protein was reported to be
present in different concentration in colostrum and
mature milk samples [49, 50, 58–60]. Our results show
that the water phase contained an order of magnitude
higher level of MCP-1 compared to the lipid phase, espe-
cially in the first 3 months of lactation. We hypothesize
that the presence of this factor influences the early postna-
tal adaptation of the immune system, mainly the
gut-associated lymphatic tissue (GALT).
One of the selected chemokines, RANTES, modulates
the homing and trafficking of monocytes and T-cells. The
presence of RANTES in non-lactating mammary epithelial
cells was proven with immunohistochemistry [60]. It plays
a role in chemotaxis and also promotes leukocyte infiltra-
tion during inflammation [61]. Previous examinations
measured elevated values in early lactation [49, 58, 62].
Since in breast milk we detected RANTES only in low
concentrations, we suggest that it has little immunological
impact.
Two of the examined factors were cytokines, CD40 and
Flt-3L. CD40 is expressed by a variety of cells, such as
monocytes, B-cells, antigen presenting cells, endothe-
lial cells, smooth muscle cells, and fibroblasts [63]. Pre-
sumably, the maternal T-cells interact with B cells of the
newborn and stimulate the immune system because
T-cells of infants are immature. Presumably, CD40 plays a
role in the immunological adaptation of the adequate im-
mune responses to unknown agents.
We also examined the growth factor EGF, which was
present in one of the highest concentrations among the
analyzed bioactive factors in the 3 layers of human milk.
The level of EGF in colostrum is 2000 times higher than
in maternal serum and 100 times higher than in foremilk
[27]. Based on previous examinations EGF is resistant
against low pH and digestive enzymes. Therefore, the
water phase of milk may reach the surface of epithelium
in the whole length of the gastrointestinal tract. Due to
immature cell connections of the epithelium, EGF can
spread into the circulation [64, 65]. EGF stimulates
DNA synthesis of enterocytes and enables their differen-
tiation [66, 67].
To our knowledge, no data exist about the presence of
Flt-3L and MDC in breast milk. Lyman and coworkers
previously proved that Flt-3L stimulates the primitive
hematopoietic stem cell progenitors’ proliferation [23]
and it also promotes T cell activation [68]. Since this
factor can be absorbed into the circulation, the question
is raised whether it may participate in the development
of the hematopoietic system and in the development of
adaptive immunity.
One of the constitutively expressed chemokines is
MDC, the expression of which is enhanced by lipopoly-
saccharides and primary proinflammatory cytokines in
macrophages [69]; it is also produced by thymus epithe-
lial cells and expressed by the hematopoietic system
[70]. The production of MDC has been observed in Th1
and Th2 cells [20], and it plays a role in type II reactions
in atopic dermatitis in humans [71]. We measured the
chemokine MIP-1ß in low concentration as in a previous
study [72]. MIP-1ß is crucial for the development of
appropriate immune responses and the mediation of
inflammation [22]. It is a potent chemoattractant of T
lymphocytes and attracts exclusively activated T-cells
[73]. In human milk, MDC and MIP-1ß are presumably
playing important roles in the adaptation of immune
system through the differentiation of T cells and may
influence the development of T-cell mediated immune
responses.
Conclusions
Milk provides not only the building blocks for develop-
ment but also the endocrinological and hormonal signals
that contribute to the biophysiological organization of
the infant. The separation of human milk into different
fractions enables analyzing the presence and concentra-
tion of various bioactive factors that may be present in
low concentrations in human milk yet have significant
biological effects. The present study showed that the
water phase is not the only influential part of breast
milk, but the MFGs in the lipid layer contain important
bioactive compounds. Our analysis provides a more
(See figure on previous page.)
Fig. 1 Concentration of CD40, RANTES, MCP-1 and EGF between the 1–3 and 4–6months of lactation in the three separated layers of breast milk: water
phase [W], water fraction of lipid phase [L-WF] and lipid fraction of lipid phase [L-LF]. 1A: CD40; 1B: EGF; 1C: MCP-1; 1D: RANTES. a CD40 ***P< 0.0001 vs W,
b EGF ***P < 0.0001 vs W, ##P< 0.01 vs L-WF, #P< 0.05 vs L-WF, c MCP-1 ***P < 0.0001 vs W, d RANTES ***P< 0.0001 vs W, #P < 0.05 vs L-WF. Note.
CD40 = cluster of differentiation 40; MCP-1 =macrophage chemokine protein-1; RANTES = regulated on activation, normal T cell expressed and
secreted; EGF = epidermal growth factor
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complete picture of the fluctuating levels of factors in
breast milk since we measured the composition of breast
milk through the first 6 months of life. Based on our
work, EGF and the analyzed cytokines and chemokines
are present in breast milk during the first 6 months of
lactation, including Flt-3L and MDC, which have not
previously been reported as present in breast milk.
These agents may be absorbed from the oral cavity from
the water phase of human milk and they can spread to
every organ of the infant. Factors present in the lipid
fraction are protected, so they are able to reach the
lower gastrointestinal tract where they may have a local
effect on gut mucosa or systemic effects through absorp-
tion into the circulation. Further research will be re-
quired to detect the concentration ranges within which
these factors are essential and beneficial for the develop-
ment of newborns.
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